Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Response Remune Trials To Continue After Agouron Drops Rights

Executive Summary

Immune Response Corporation will continue clinical trials for the HIV therapy Remune (HIV-1 immunogen) following the decision by Pfizer subsidiary Agouron to drop its rights to develop and market the product, IRC said July 6.

You may also be interested in...



Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?

Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors

Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?

Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors

Remune Virologic Response Data Is At Center Of Publication Dispute

The dispute between a University of California at San Francisco researcher and Immune Response over publication of results from a Remune study focuses on the presentation of virologic response data.

Related Content

UsernamePublicRestriction

Register

PS038145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel